On October 19, Disc Medicine and EyePoint Pharmaceuticals reported contrasting results from their respective Phase 3 clinical trials. Disc Medicine announced that its APOLLO trial for bitopertin successfully met all primary and secondary endpoints. In contrast, EyePoint Pharmaceuticals disclosed that its LUCIA trial for DURAVYU failed to meet its primary endpoint of statistical non-inferiority. These developments represent significant clinical milestones for both biotechnology companies.
The company plans to resubmit its application for bitopertin approval by the end of 2026, while EyePoint is cutting staff and redirecting resources after an eye disease trial missed a primary endpoint.
Read the full story